DMPK Insights #2: Pathways to Successful Drug Design – Discovery Metabolite ID
About this Podcast on Drug Design and Discovery Metabolite ID
The episode addresses the following questions:
- Why studying biotransformation is an important part of early drug design
- A strategy to combine in silico tools, high-resolution MS and software-assisted data analysis to optimize data delivery and quality
- How this influences medicinal chemistry and the design–make–test cycle
In this podcast, Dan Weston, Scientific Leader, Biotransformation at GSK discusses his recent publication on the important role that Metabolite ID plays in drug discovery.
Capabilities
Speaker:
Dan Weston, Ph.D. – Scientific Leader, Biotransformation at GSK
Dan gained his Ph.D. in ion-trap mass spectrometry from Nottingham Trent University. He has held positions at Unilever (environmental fate using LC-MS); Schering-Plough (US) (small-molecule Met-ID for drug discovery); Nottingham Trent University (designing and building novel ion-mobility instrumentation); AstraZeneca (Met-ID for drug development); Waters (demo chemist, utility of ion mobility for small molecule applications); Sygnature (Met-ID Team Leader); and currently at GSK (Scientific Leader; providing cross-portfolio biotransformation support). His research interests include structural elucidation using novel mass spectrometric approaches; complementary analytical techniques such as ion mobility for data rationalization and insights into metabolite structure; in silico approaches for efficient data analysis; ambient ionization and rapid sample screening techniques
Reference:
Weston, D.J., Dave M., Colizza K. et al., 2022. A discovery biotransformation strategy: combining in silico tools with high-resolution mass spectrometry and software-assisted data analysis for high-throughput metabolism, Xenobiotica, 52(8): 928-942
Also available on:
Stay tuned for more podcasts in our Pharmaron DMPK Insights Series!